Early Rivaroxaban Use After Cardioembolic Stroke May Not Result in Hemorrhagic Transformation

Abstract

These data support the safety of rivaroxaban initiation ≤14 days of mild-moderate cardioembolic stroke/transient ischemic attack. Magnetic resonance imaging evidence of petechial HT, which is common, does not appear to increase the risk of symptomatic HT.